KOSDAQBiotech & Pharma290650

L&C Bio

₩20,250▲ 4.44%2026-11-18 close
Market Cap
₩1.2T
Turnover
₩9.1B
Volume
450K
Shares out.
61.1M
PER
—
PBR
3.7×
EPS
-₩1,526
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

Lituo drives operating turnaround; net income still volatile

L&C BIO's operating profit has risen for three straight quarters on Lituo sales, while net income attributable to controlling shareholders swings between profit and loss because of convertible bond valuation effects.

  1. 1

    Third-quarter 2026 sales reached KRW 38.4 billion, up 70.4% year on year, and operating profit reached KRW 9.84 billion, up 239.8%.

  2. 2

    Cumulative sales for January to September 2026 rose 76.8% to KRW 107.5 billion, and cumulative operating profit rose 892.1% to KRW 24.4 billion, based on the November 9, 2026 disclosure.

  3. 3

    Lituo capacity is currently 80,000 units a month, with equipment for 150,000 units a month planned to be ready within 2026 and expansion output scheduled from 2027.

  4. 4

    Net income attributable to controlling shareholders has repeatedly dipped into losses, including a KRW 72.6 billion loss in the fourth quarter of 2025 and a KRW 28 billion loss in the second quarter of 2026, which press reports attributed to convertible bond valuation losses.

  5. 5

    The debt-to-equity ratio stood at 119.0% at the end of 2025, and KRW 105 billion of the planned KRW 140.6 billion rights offering is allocated to facility investment in Dongtan.

02

Business structure

L&C BIO's core business is tissue grafts made from processed human tissue, complemented by tissue-based medical devices, pharmaceuticals, and cosmeceuticals. As of June 2026, product sales were split into tissue grafts at 86.81%, medical devices at 10.02%, pharmaceuticals at 3.25%, and cosmeceuticals at 0.37%.

Within tissue grafts, MegaDerm, MegaCarti, MegaNerve Prime, and MegaFill form the stable sales base.

The growth product is Re2O, a skin ECM-based product whose quarterly sales rose from KRW 2.4 billion in the third quarter of 2025 to KRW 14.5 billion in the second quarter of 2026, according to a Sangsangin Securities report.

A Eugene Investment & Securities report put standalone 2025 sales at KRW 55.6 billion for tissue grafts, KRW 10.1 billion for medical devices, and KRW 3.1 billion for pharmaceuticals. Medical device sales in 2025 were 70.16% domestic and 29.84% export.

Customers are mainly domestic medical institutions, and Lituo supply is also expanding mainly through them. Overseas, the group includes L&C Bioscience Technology (Kunshan), which manufactures and sells medical devices in China, and L&C Medicare, a domestic medical device distributor.

The competitive base is raw tissue sourcing and production and quality control infrastructure, which the company says keeps fixed costs from rising as fast as new product sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩22.6B₩2.9B12.8%
2025Q4₩24.7B₩2B7.9%
2026Q1₩30.3B₩6B19.8%
2026Q2₩38.8B₩8.6B22.1%
2026Q3₩38.4B₩9.8B25.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩52.6B₩9.5B₩4.5B18.0%4.6%85.2%
2023₩68.9B₩7.7B₩48.4B11.3%32.9%67.2%
2024₩72.1B₩2.5B₩141.1B3.5%49.6%61.4%
2025₩85.5B₩4.4B-₩138.2B5.2%−69.7%119.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales rose from KRW 52.6 billion in 2022 to KRW 68.9 billion in 2023, KRW 72.1 billion in 2024, and KRW 85.5 billion in 2025. Sales grew for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating profit went from KRW 9.48 billion in 2022 to KRW 7.75 billion in 2023, a decline of 18.3%, then to KRW 2.54 billion in 2024, a decline of 67.2%, before recovering to KRW 4.42 billion in 2025, an increase of 73.7%. 2022 was the largest year and 2024 the smallest for operating profit.

In 2024 sales rose 4.7% while operating profit fell 67.2%, pushing the operating margin down to 3.5%, which recovered slightly to 5.2% in 2025.

Net income attributable to controlling shareholders grew from KRW 4.54 billion in 2022 to KRW 48.4 billion in 2023 and KRW 141.1 billion in 2024, then turned into a net loss of KRW 138.2 billion in 2025.

Quarterly sales rose 9.4% to KRW 24.7 billion in the fourth quarter of 2025 while operating profit fell 32.5% to KRW 1.95 billion, which marked the low point.

Sales then reached KRW 30.3 billion, KRW 38.8 billion, and KRW 38.4 billion in the first three quarters of 2026, and operating profit rose to KRW 6 billion, KRW 8.58 billion, and KRW 9.84 billion over the same period, growing for three straight quarters.

Net income attributable to controlling shareholders swung to a KRW 2.6 billion profit in the first quarter, a KRW 28 billion loss in the second, and a KRW 4.7 billion profit in the third.

Press reports attributed the second-quarter loss to fair value losses on the third convertible bonds' conversion and redemption rights as the share price rose, not to operating losses. Cumulative consolidated operating margin for the first nine months of 2026 was 22.7%, up from 4.0% a year earlier. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 93.2 billion.

05

Industry analysis

In the skin regeneration and skin booster segment, Lituo has established itself as a growth driver as domestic medical institutions absorb supply quickly. The company presents this trend as evidence of the profitability and growth potential of its ECM platform.

For tissue grafts, demand is rising on localization and wider indications, and the company says growing cancer patients and a focus on quality of life are widening demand for allogeneic tissue grafts.

In the first half of 2026, consolidated sales rose 80.4% and operating profit turned to a profit, so revenue expansion and margin improvement arrived at the same time. Securities analysts interpret this as operating leverage, in which sales growth flowed into profit without a matching rise in fixed costs.

The current stage looks like rapid domestic supply expansion, and securing overseas demand is the task identified for filling capacity above KRW 1 trillion. On the competitive side, aesthetic treatments include listed rivals such as Hugel, so product selection by medical institutions is a variable that affects results.

Secure access to raw human tissue and GTP production facility approval are cited as barriers that new entrants cannot easily overcome.

06

Outlook

The company has set medium- to long-term targets of KRW 1 trillion in sales and KRW 300 billion in operating profit by 2030. The first step is expanding production capacity.

Lituo capacity is currently about 80,000 units a month, with equipment for 150,000 units a month to be prepared within 2026 and expansion output running in earnest from 2027.

The company plans to begin construction of a new Dongtan production plant soon, and it aims to lift capacity above KRW 1 trillion once the integrated Dongtan plant is complete.

To fund this, the board approved a rights offering of 3.7 million common shares on July 31, 2026, and allocated KRW 105 billion of the KRW 140.6 billion planned proceeds to facility funds in Dongtan, with KRW 20.6 billion for operations and KRW 15 billion for debt repayment.

The company appears to have shifted its strategy from building a separate US plant toward producing domestically and exporting overseas.

In a March 2026 report, Eugene Investment & Securities estimated 2026 sales at KRW 123.1 billion, so reaching that estimate depends on fourth-quarter sales given cumulative sales of KRW 107.5 billion through September.

On the same day, the company decided to acquire and fully retire the KRW 15 billion balance of its third convertible bonds, and it plans to review further shareholder returns such as buybacks, cancellations, and dividends.

07

Valuation

PER
—
PBR
3.7×
ROE
-31.8%
EPS
-₩1,526
BPS
₩5,413
Dividend per share
—

Because net loss attributable to controlling shareholders over the last four quarters totals KRW 93.2 billion, the PER cannot be calculated. With earnings-based metrics limited, PBR becomes the main reference for valuation.

The current PBR reflects a premium to net asset value, and total equity at the end of 2025 was KRW 208.5 billion, of which KRW 198.2 billion belonged to controlling shareholders. How asset-based multiples read will depend on how much equity grows through the capacity investment and the rights offering.

The rights offering represented a 13.72% increase in shares issued, while the retirement of the KRW 15 billion convertible bond balance reduces potential share issuance.

Dividends are small, which limits valuation on a dividend basis, and the company says it is reviewing further shareholder returns including buybacks, cancellations, and dividends.

Cumulative operating profit of KRW 24.4 billion for the first nine months of 2026 is a profit base, but large swings in net income widen the range of valid multiple readings. The next checkpoint for valuation is when steady earnings accumulate enough to make the PER calculable.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Steep growth in Lituo sales

According to a Sangsangin Securities report, Lituo sales rose from KRW 2.4 billion in the third quarter of 2025 to KRW 14.5 billion in the second quarter of 2026. Cumulative consolidated operating margin for January to September 2026 was 22.7%, up from 4.0% a year earlier, and standalone margin reached 29.7%. Profitability of the core business is improving alongside product expansion.

Capacity expansion and medium-term targets

Lituo capacity is set to move from 80,000 units a month to equipment readiness for 150,000 units within 2026, with expanded output from 2027. KRW 105 billion of facility funding for the integrated Dongtan plant underpins the plan to lift capacity above KRW 1 trillion.

The company has disclosed medium-term targets of KRW 1 trillion in sales and KRW 300 billion in operating profit by 2030.

Convertible bond retirement and shareholder return review

The company resolved to call and fully retire the KRW 15 billion balance of its third convertible bonds. The company says fewer convertible shares could convert, which lowers dilution and potential sell-side overhang. It also said it is reviewing further shareholder returns such as buybacks, cancellations, and dividends.

09

Bear factors

Large swings in net income

Net income attributable to controlling shareholders has repeatedly turned into losses, including a KRW 72.6 billion loss in the fourth quarter of 2025 and a KRW 28 billion loss in the second quarter of 2026. Press reports attributed the second-quarter loss to fair value losses on convertible bond rights.

Net loss attributable to controlling shareholders over the last four quarters totals KRW 93.2 billion, so reported net income can swing with convertible bond valuation even as operating profit improves.

Investment burden and financial leverage

The debt-to-equity ratio rose to 119.0% at the end of 2025 from 61.4% in 2024, with total liabilities of KRW 248.1 billion against total equity of KRW 208.5 billion. Even with the KRW 140.6 billion rights offering, the scale of plant investment keeps payback timing and financial burden as open variables.

One analysis described the Dongtan investment as large relative to current sales and noted that overseas demand must be secured for the expansion to fully pay off.

Product concentration and overseas demand challenge

As of June 2026, tissue grafts accounted for 86.81% of sales, so the business is concentrated in one segment. Exports made up 29.84% of medical device sales in 2025, with the rest domestic, so overseas share remains limited.

Lituo is supplied mainly through domestic medical institutions, so slower domestic demand could affect its growth pace.

10

Risk factors

Financial and capital structure

The debt-to-equity ratio was 119.0% at the end of 2025, with total equity of KRW 208.5 billion. The increase in share count from the rights offering could dilute per-share metrics. Convertible bond valuation gains and losses swing net income and add uncertainty to financial assessment.

Product and regulatory dependence

Tissue grafts and tissue-based devices depend on GTP production facility approval and quality control systems. Licensing or quality issues could directly affect production and supply. Because Lituo is supplied mainly through domestic medical institutions, it may be sensitive to demand and policy changes.

Expansion execution and demand balance

If equipment for 150,000 units a month and the 2027 expansion do not proceed on schedule, supply and demand may fall out of balance. Conversely, if demand does not keep pace after expansion output starts, fixed-cost pressure would increase. One securities analysis described the Dongtan investment as ahead of current business scale.

11

What to watch next

  1. November 23, 2026

    Scheduled payment date for acquiring the third convertible bonds. Completion of the retirement would confirm a reduction in potential share issuance.

  2. By end of December 2026

    Whether equipment for 150,000 units a month is ready and construction of the Dongtan plant starts as planned. Alignment with the 2027 expansion schedule is the key point.

  3. March 31, 2027 (statutory deadline for the annual report)

    The 2026 annual report is the next regular filing. Check how far full-year sales exceed the KRW 107.5 billion cumulative for January to September and how the debt-to-equity ratio changes.

  4. Mid-May 2027 (typical schedule)

    Whether Lituo sales and operating margin hold in the first-quarter results, and how much net income attributable to controlling shareholders depends on convertible bond valuation.

  5. During 2027

    Whether expansion output is running in earnest, whether the integrated Dongtan plant is completed, and whether overseas sales share expands.

12

Overall view

L&C BIO's 2026 is a period in which Lituo sales growth and capacity expansion have lifted operating profit. Cumulative sales for January to September 2026 reached KRW 107.5 billion and operating profit reached KRW 24.4 billion, with operating profit rising for three straight quarters.

Bullish factors are quarterly growth in Lituo sales, recovery in operating margin, capacity expansion from 80,000 to 150,000 units a month, and reduced share overhang from the bond retirement.

Bearish factors are net income attributable to controlling shareholders swinging between profit and loss each quarter on convertible bond valuation, the net loss of KRW 138.2 billion in 2025, the 119.0% debt-to-equity ratio at the end of 2025, and the need to secure overseas demand for a large expansion.

These factors deserve equal weight, and both sustained operating profit and stabilized net income need to be confirmed. The next checkpoints are the 2026 annual report, first-quarter 2027 results, and whether construction at Dongtan starts and expansion output runs. This report contains no investment opinion, rating, or target price and is provided for information only.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. newstown.co.kr
  2. news1.kr
  3. kormedi.com
  4. m.news.nate.com
  5. hankyung.com
  6. specialtimes.co.kr
  7. dealsite.co.kr
  8. comp.wisereport.co.kr
  9. view.asiae.co.kr
  10. vegannews.co.kr
  11. m.jobkorea.co.kr
  12. file.alphasquare.co.kr
  13. pmstoryhub.com
  14. navercomp.wisereport.co.kr
  15. file.alphasquare.co.kr
  16. pharm.edaily.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis